<DOC>
	<DOCNO>NCT02170727</DOCNO>
	<brief_summary>To demonstrate effectiveness Daclatasvir ( DCV ) 3 Direct Acting Antivirals ( DAA ) fix dose combination Genotype 1 Chronic Hepatitis C subject .</brief_summary>
	<brief_title>A Phase 3 Study Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination ( FDC ) Subjects With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description>US National Institutes Health Division AIDs ( DAIDS )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subject chronically infect HCV genotype 1 ( GT1 ) Subject without cirrhosis compensate cirrhosis ( Child Pugh Class A ) HCV RNA ≥ 10,000 IU/mL screen Treatmentnaïve subject previous exposure interferon formulation ( ie , IFNα , pegIFNα ) , Ribavirin ( RBV ) , HCV DAA ( protease , polymerase inhibitor , etc . ) Interferon ( IFN ) experience subject receive previous treatment IFNα , without RBV Liver transplant ( include hematopoietic stem cell transplant ) cornea hair ; Current known history cancer ( except situ carcinoma cervix adequately treat basal squamous cell carcinoma skin ) within 5 year prior screen ; Documented suspect hepatocellular carcinoma ( HCC ) , evidence previously obtain image study liver biopsy ( screen image study/liver biopsy perform ) ; Evidence decompensated liver disease include , limited , radiologic criterion , history presence ascites , bleed varix , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>